


# PRESCRIBING PSYCHOTROPICS

*From Drug Interactions  
to Genetics*

**Sample Pages**

Available with 10 CME Credits at [www.thecarlatreport.com](http://www.thecarlatreport.com)



**Chris Aiken, MD**  
**Joshua D. Feder, MD**  
**Daniel J. Carlat, MD**

# PRESCRIBING PSYCHOTROPICS

*From Drug Interactions to Genetics*

**FOURTH EDITION**

(Previously *Drug Metabolism in Psychiatry*)

## **Chris Aiken, MD**


Editor-in-chief of *The Carlat Psychiatry Report*, host of *The Carlat Psychiatry Podcast*, and director of the Mood Treatment Center in North Carolina

## **Joshua D. Feder, MD**

Editor-in-chief of *The Carlat Child Psychiatry Report*, contributor to *The Carlat Psychiatry Podcast*, practicing psychiatrist in Solana Beach, CA, and medical director at Positive Development

## **Daniel J. Carlat, MD**

Publisher of *The Carlat Psychiatry Report*, *The Carlat Child Psychiatry Report*, *The Carlat Addiction Treatment Report*, and *The Carlat Hospital Psychiatry Report*, and associate clinical professor at Tufts University School of Medicine, Boston, MA



Sample Page

***Prescribing Psychotropics:  
From Drug Interactions to Genetics***

Available with 10 CME Credits at [www.thecarlatreport.com](http://www.thecarlatreport.com)

**Prescribing Psychotropics: From Drug Interactions to Genetics**  
**FOURTH EDITION**

(Previously *Drug Metabolism in Psychiatry*)

Published by Carlat Publishing, LLC  
PO Box 626, Newburyport, MA 01950

**Publisher and Editor-in-Chief:** Daniel J. Carlat, MD  
**Deputy Editor:** Talia Puzantian, PharmD, BCPP

**Executive Editor:** Janice Jutras

All rights reserved. This book is protected by copyright.


This CME/CE activity is intended for psychiatrists, psychiatric nurses, psychologists, and other health care professionals with an interest in mental health. The Carlat CME Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Carlat CME Institute maintains responsibility for this program and its content. Carlat CME Institute designates this enduring material educational activity for a maximum of ten (10) AMA PRA Category 1 Credits™. Physicians or psychologists should claim credit commensurate only with the extent of their participation in the activity. The American Board of Psychiatry and Neurology has reviewed *Prescribing Psychotropics: From Drug Interactions to Genetics* and has approved this program as part of a comprehensive Self-Assessment and CME Program, which is mandated by ABMS as a necessary component of maintenance of certification. CME tests must be taken online at [www.thecarlatreport.com](http://www.thecarlatreport.com) or <https://www.thecarlatreport.com/about/about-cme-center> (for ABPN SA course subscribers).

To order, visit [www.thecarlatreport.com](http://www.thecarlatreport.com) or call (866) 348-9279

1 2 3 4 5 6 7 8 9 10

ISBN: 978-1-7329522-6-3

ISBN: 978-1-7329522-7-0



Sample Page

**Prescribing Psychotropics:  
From Drug Interactions to Genetics**

Available with 10 CME Credits at [www.thecarlatreport.com](http://www.thecarlatreport.com)


# Table of Contents

Acknowledgments .....	iv
Preface .....	v
<b>SECTION I: THE BASICS .....</b>	<b>1</b>
Chapter 1. Introduction: An Overview of Drug Metabolism and a Road Map to the Book .....	3
Chapter 2. Pills, Capsules, and Wafers: How Drugs Are Formulated and Why It Matters .....	7
Chapter 3. GI Absorption, Distribution, and the Blood-Brain Barrier .....	15
Chapter 4. Basic Pharmacokinetics: Onset, Duration, and Half-Life .....	21
Chapter 5. Modified-Release Medications: XR, CR, ER, and Beyond .....	33
Chapter 6. Transdermal and Intranasal Delivery .....	53
Chapter 7. Injectable Medications .....	61
Chapter 8. Biotransformation and the Liver .....	75
Chapter 9. Excretion .....	85
<b>SECTION II: DRUG INTERACTIONS .....</b>	<b>97</b>
Chapter 10. Drug Interactions .....	99
Chapter 11. Drug Interactions: Antidepressants .....	109
Chapter 12. Drug Interactions: Antipsychotics and Mood Stabilizers .....	117
Chapter 13. Food and Drink Effects on Medications .....	125
Chapter 14. Recreational Drug Interactions .....	131
Chapter 15. Pharmacodynamic Drug Interactions .....	135
<b>SECTION III: SPECIAL TOPICS .....</b>	<b>153</b>
Chapter 16. Generic Medications and Drug Metabolism .....	155
Chapter 17. Pharmacogenetic Testing .....	169
Chapter 18. Prescribing for the Elderly and the Young .....	181

Sample Page

***Prescribing Psychotropics:  
From Drug Interactions to Genetics***

Available with 10 CME Credits at [www.thecarlatreport.com](http://www.thecarlatreport.com)



## Preface

Most of our education as psychiatrists consists of learning how to diagnose patients and then learning how to choose the right treatment. This is important stuff. For example, I recently admitted a 36-year-old woman to the inpatient unit. The day before, she had been observed by neighbors trying to open the doors of several other apartments in her complex. When confronted, she screamed at them and said that “all these domiciles are my own.” The police were called, and she was admitted on an involuntary basis to our unit.

My training enabled me to quickly establish rapport, arrive at a diagnostic differential (I entertained bipolar disorder, schizophrenia, and schizoaffective disorder, among others), and efficiently ask the right questions to rule those diagnoses in or out. I decided that she was suffering a manic episode, and my psychopharmacology training directed me to the most efficacious cocktail for quelling acute mania—a combination of a mood stabilizer, an antipsychotic, and a benzodiazepine.


But here’s where the difficult decisions really begin, for this patient and others like her. Which mood stabilizer? I chose lithium. But which version of lithium? Should I start it in the morning or at night? How frequently should I dose it? When should I draw a blood level? Should I worry about other drugs the patient might be taking, such as ibuprofen for a sprained ankle?

The secret of excellent psychiatric treatment lies in the detailed answers to such questions. Over the course of our careers, we gradually learn about how different formulations of a given drug can make a big difference, how timing blood draws helps us titrate doses, how drugs can interact with one another, etc. But these lessons take many years to learn, and the answers change periodically as we learn more and with the development of new medications, new kinds of medications, and new technologies such as pharmacogenetics. There are few textbooks that focus explicitly on the details of drug metabolism and formulation—details that end up making the difference between superior treatment and treatment that is just “good enough.”

Sample Page

***Prescribing Psychotropics:  
From Drug Interactions to Genetics***

Available with 10 CME Credits at [www.thecarlatreport.com](http://www.thecarlatreport.com)



## CHAPTER 1

# Introduction: An Overview of Drug Metabolism and a Road Map to the Book

**LET'S BEGIN THIS JOURNEY** with a very basic question. Why do we need drug metabolism at all?


The best thinking among pharmacologists is that metabolism started when early organisms realized that they could improve their chances of survival by producing toxins and delivering them to potential predators. While poisoning enemies was good fun, a problem arose: how to avoid poisoning themselves. Metabolic enzyme systems therefore initially evolved in order to get rid of these endogenous toxins, but they turned out to be quite good at neutralizing exogenous toxins as well, such as food byproducts and (fast-forward a billion years) modern pharmaceuticals.

In order for drugs to work, they need to get into our system and into our cells. First, that means that the drug molecules have to be packaged in a delivery system that patients find attractive and are willing to swallow (see Chapter 2 on the secrets of pills and capsules)—or, sometimes they might be more efficiently delivered as patches, intranasally, or as injectables (see Chapters 6 and 7). Once the medications get into our system, they have to be absorbed and distributed. For GI absorption to happen, the stomach must grind down pills and capsules so that the molecules can come into contact with intestinal villi, where most of the actual absorption into the stream takes place.

### Sample Page

## *Prescribing Psychotropics: From Drug Interactions to Genetics*

Available with 10 CME Credits at [www.thecarlatreport.com](http://www.thecarlatreport.com)



the AUC represents the entire amount of drug that is present in the blood over a given period of time. Chapter 4 focuses on half-life, steady state, and the whole field of pharmacokinetics.


After drugs have worked their magic, we have to get rid of them. How do we accomplish this? The answer, which we discuss in Chapters 8 and 9, is that we transform them into water-soluble versions of themselves, so that they can be swept away in (watery) urine or stool. To do this, we use cytochrome P450 enzymes and glucuronidation, which you'll learn about in Chapter 8 as well.

By the way, as part of our effort to explain drug excretion in Chapter 9, we offer you our take on the kidney, that intimidating organ that we all know we should know more about but have been studiously avoiding. We show you that the kidney is made up of nephrons that do the work of drug excretion, and how understanding the process of tubule absorption will help you feel comfortable prescribing lithium and knowing when to order lithium levels.

Before drugs get excreted, they spend some time in the bloodstream, hopefully getting into the brain and doing something constructive for our patients (see Chapter 3 for an explanation of the blood-brain barrier). Along the way, they may encounter other drugs, leading to drug-drug interactions. We cover such interactions in Chapters 10, 11, and 12, and also focus on drug-food interactions that aren't as well known (Chapter 13) and interactions with recreational drugs (Chapter 14).

In Chapter 15 we cover the very important topic of *pharmacodynamic* interactions, in which some of our drugs combine forces with other drugs to cause potentially fatal assaults on the brain, such as serotonin syndrome and MAOI-induced hypertension. In that same chapter, we remind you of the dangers of anticholinergic interactions and how to minimize them in your patients.

Throughout the text, we try to keep a practical eye on how these concepts apply to your prescription pad. Toward that end, the new edition features extensive coverage of three trends that have expanded since the first



## Sample Page

# Prescribing Psychotropics: From Drug Interactions to Genetics

Available with 10 CME Credits at [www.thecarlatreport.com](http://www.thecarlatreport.com)

## CHAPTER 2

# Pills, Capsules, and Wafers: How Drugs Are Formulated and Why It Matters

A **PSYCHOPHARMACOLOGIST PRESCRIBES** thousands of pills over a career but is likely to have very little idea of how those medications are manufactured and formulated. In this chapter, we'll help to remedy this knowledge gap.

### Some Definitions

The word “pill” comes from the Latin *pillula*, meaning a little ball or pellet. The term was first used in its medical sense in the 1400s and referred to a package of medicinal herbs with inert substances rolled into a sphere.

In modern usage, “pill” and “tablet” are interchangeable and refer to solid forms of medicines. They are manufactured by combining the powdered active molecule with inactive fillers called *excipients*. Those ingredients are then compressed together into a shape and size that is easily swallowed. The excipients are used for various reasons, including to bulk up the medicine so it's big enough to handle; to give the outer layer a pleasing taste, texture, or color; to help preserve the medicine; and to enhance the medicine's ability to effectively dissolve in the GI tract.

Unlike pills and tablets, capsules are not solid. Capsules are dissolvable shells that contain a powder or liquid form of the medication.


### VEGAN MEDICINES?

Many capsule shells are made of gelatin from animal collagen.


Sample Page

**Prescribing Psychotropics:  
From Drug Interactions to Genetics**

Available with 10 CME Credits at [www.thecarlatreport.com](http://www.thecarlatreport.com)



The small intestine contains millions of villi and microvilli in its folds, providing an absorptive area about the size of a tennis court. Now that's a lot of absorption.



**FIGURE 3-1. The GI System**


Once drugs are absorbed by the GI tract, they go into the hepatic portal circulation to the liver. This delay before delivery to the target tissues is famously known as the “first-pass effect” because drugs pass first through the liver en route to the heart. Depending on the drug, the liver may metabolize well over 50% of the active ingredients before they arrive at the brain.

There are, however, two regions of the GI tract that drain into vessels that go directly to the heart, bypassing the greedy liver: the sublingual area (under the tongue) and the rectal area. When administered sublingually, drugs can get to work faster and in higher concentrations. We use drugs this way when rapid onset of action is crucial. Sublingual

Sample Page

**Prescribing Psychotropics:  
From Drug Interactions to Genetics**

Available with 10 CME Credits at [www.thecarlatreport.com](http://www.thecarlatreport.com)



dose, resulting in a day 2 max of 300 mg + 600 mg = 900 mg. On day 3, he starts the day with half of 900 mg, or 450 mg, and after his 600 mg dose he has 1050 mg. And so on. As you can see, with each passing day, the blood levels—both peak and trough—become more and more predictable. They still fluctuate by 600 mg a day, but the peak and trough are relatively stable.

And this explains why we wait 5 half-lives before drawing a blood level. At day 2, the trough blood level would be 300, and at day 3, it would be 450. There’s a big difference between 300 mg and 450 mg, which shows why drawing blood levels too early yields unreliable results. However, a blood level draw at day 5 (562) is not much different from day 7 (590), which in turn will not be much different from the result on day 300, as long as the dose stays at 600 mg. Eventually, a limit is reached, with the peak hovering around 1200 and the trough around 600.

Body Content of Lithium in Milligrams	Day 1		Day 2		Day 3		Day 4	
	Max	Min	Max	Min	Max	Min	Max	
600	600	300	900	450	1050	525	1125	
	Day 5		Day 6		Day 7			
	Min	Max	Min	Max	Min	Max		
	562	1162	581	1181	590	1190		

**FIGURE 4-2. How Lithium Rises When Dosed 600 mg QHS**

**VERDICT**

It takes 5 half-lives to achieve steady state, and that’s how long you need to wait before checking a serum level on drugs like lithium, valproate, or carbamazepine. If you check any earlier, your trough level will underestimate the actual level that the patient will achieve after steady state.

## Do Drugs With Long Half-Lives Take Longer to Work?

There’s a strange myth floating around that drugs with long half-lives take longer to work than drugs with short half-lives. Apparently, this comes from a misunderstanding of the meaning of steady state. It’s true that long half-life drugs take longer to reach steady state. For example, fluoxetine, in concert with its metabolite, takes 2 to 3 weeks to reach steady state. But once it does, it stays there for a long time. Short half-life drugs, on the other hand, reach steady state much more quickly, but they also leave the system much more quickly.

Sample Page

**Prescribing Psychotropics: From Drug Interactions to Genetics**

Available with 10 CME Credits at [www.thecarlatreport.com](http://www.thecarlatreport.com)




TABLE 7-2. LAI Antipsychotic Medications

LAI Antipsychotic	Dosing	Release Date	Pros and Cons
Abilify Maintena	Monthly	2013	Well tolerated and effective, although requires a 2-week overlap of oral aripiprazole
Aristada (aripiprazole lauroxil)	Every 6–8 weeks	2017	Well tolerated, effective, and long lasting, although meant to be used after a single dose of Aristada Initio
Aristada Initio (aripiprazole lauroxil)	Single dose initiation	2018	Well tolerated and effective, although meant as a one-time use followed by Aristada
Haloperidol decanoate	Every 2 weeks	1982	Simple conversion from oral, but more frequent administration
Invega Sustenna	Every month	2009	Not approved for mania; not tested for bipolar depression; expensive
Invega Trinza	Every 3 months	2015	Longest lasting, but requires 4 months of Invega Sustenna first
Prolixin decanoate (fluphenazine)	Every 2–4 weeks	1972	First in class and an important advance; however, discontinued in 2018 due to single supplier unable to deliver reliably
Risperdal Consta	Every 2 weeks	1993	More research on efficacy, but 3-week oral overlap and then injections every 2 weeks
Zyprexa Relprevv	Every 2–4 weeks	2009	Low rate of EPS, but rare delirium requires 3-hour observation after injection and registration as a prescriber


## Aristada Initio (Aripiprazole Lauroxil Nanocrystal Suspension)

*Mechanism of release:* Aripiprazole lauroxil is also available as a nanocrystal suspension. Like we saw with the earlier Aristada, the prodrug is first hydrolyzed to N-hydroxymethyl aripiprazole, then hydrolyzed again to aripiprazole. For this preparation, however, the smaller particle size makes the particles dissolve faster to reach therapeutic levels more rapidly.


### Sample Page

## Prescribing Psychotropics: From Drug Interactions to Genetics


Available with 10 CME Credits at [www.thecarlatreport.com](http://www.thecarlatreport.com)



EFFECT #1



EFFECT #2



**FIGURE 15-1. “Double Whammy” Effect of Ingesting Tyramine With MAOI on Board**

for MAO-B. This receptor is not involved in depression, so oral selegiline’s antidepressant effects don’t kick in until the dose gets high enough for its inhibitor effects to spread to MAO-A (around 30 mg/day of oral selegiline). At that dose, it also inhibits MAO-A in the gut and requires the same dietary precautions as traditional MAOIs.


Transdermal selegiline (EMSAM) was developed to get around this problem. The medication passes directly into the bloodstream through the skin, bypassing the liver and GI tract. This, in turn, yields two metabolic benefits. First, because transdermal selegiline’s concentration in the GI tract is much lower than the oral version, there is less inhibition of dietary tyramine’s metabolism, and so less concern about dietary restrictions.

Second, because there is no first-pass effect through the liver, a relatively

Sample Page

*Prescribing Psychotropics:  
From Drug Interactions to Genetics*

Available with 10 CME Credits at [www.thecarlatreport.com](http://www.thecarlatreport.com)



# Index

[NOTE] Page numbers followed by *f* indicate figures; *t* indicates a table.

## A

Abilify. *see* Aripiprazole  
Absorption. *see also* specific type  
  after bariatric surgery, 17  
  children, 186  
  elderly patients, 181–182  
  food, 125–128  
Acetaldehyde, drug interactions, 133  
Active metabolites, 101–102  
Adasuve. *see* Loxapine  
Adderall, 50  
ADHD medications, QTc burden of,  
  150–152  
Alcohol, drug interactions, 133  
Alcoholic liver disease, 79  
Allergic reactions, to inactive ingredients,  
  13–14  
Alpers-Huttenlocher syndrome, 174  
Ambien. *see* Zolpidem  
Amphetamines, 50–51  
  mixed salts, 51t  
  racemic, 51t  
Angiotensin-converting enzyme (ACE)  
  inhibitors, 92  
Angiotensin receptor blockers (ARBs), 92  
Anticholinergics, 64–66  
  burden, 147–149, 148t  
  human cost, 147t  
Anticonvulsants  
  drug interaction, 119–124  
  generic, 162  
  modified-release, 42–46  
Antidepressants  
  with active metabolites, 114t  
  augmentation of MAOIs, 146  
  drug interactions, 109–115  
  generic, 161–162

  drug levels, 117–118  
  generic, 160  
  long-acting injectable, 66–71  
  QTc burden of, 150  
  short-acting IM, 63–64  
Aplenzin. *see* Bupropion  
Area under the curve (AUC), 3–4, 22  
Aripiprazole  
  IM, 64  
  long-acting IM, 68–69  
Aripiprazole lauroxil, long-acting IM, 68  
Aripiprazole lauroxil nanocrystal  
  suspension, long-acting IM, 69  
Aristada. *see* Aripiprazole lauroxil  
Aristada Initio. *see* Aripiprazole lauroxil  
  nanocrystal suspension  
Armodafinil, 27  
Aromatherapy, 59  
Asenapine  
  sublingual, 54–55, 55t  
  transdermal, 54–55, 55t  
Ativan. *see* Lorazepam  
Authorized generic drugs, 157–158


## B

Bariatric surgery, drug absorption after, 17  
Benign ethnic neutropenia (BEN),  
  clozapine in African Americans, 195  
Benzedrine, 50  
Benzodiazepines  
  generic, 163  
  half-life of, 24t, 24–26  
  IM, 64–66  
  patients on opioids, 136t  
  pharmacodynamic drug interactions,  
  135–137

## Sample Page

# Prescribing Psychotropics: From Drug Interactions to Genetics

Available with 10 CME Credits at [www.thecarlatreport.com](http://www.thecarlatreport.com)



Blood-brain barrier (BBB), 15–20  
 pharmacokinetics at, 177–178

Branded generic drugs, 157–158

Bremelanotide, SC injectable, 72

Brexanolone, IV, 73

Bupropion, 37, 38–41, 40f  
 augmentation, 114–115  
 formulations, 39t  
 seizure risk and, 38–39

## C

Caffeine, 93

Capsules

vs pills, 8

pros and cons, 8t

Carbamazepine, 31, 45–46, 119–121, 121t

Carbamazepine XR, 37

Carbatrol. *see* Carbamazepine

Carlat Charts, how to use, 199–200

CBD oil, drug interactions, 133–134

Children, drug metabolism in, 186–187

Chlorpromazine. *see* Aripiprazole

Cirrhosis, 80–82, 81t

Clonidine patch, 56

Clozapine, 118

benign neutropenia and, 195  
 generic, 160

Clozaril. *see* Clozapine

Cmax, 21–22

CNSDose, 177–178

Cocaine, drug interactions, 133–134

Concentration-time curve, 22f

Concerta, 37

Conjugation, 77–78

Cymbalta. *see* Duloxetine

CYP450 system, 169–170

CYP enzymes, inhibition by psychotropics,  
 109–111, 110t, 112t

## D

Dextroana. *see* Methylphenidate patch  
 drug interactions, QTc burden, 150

Dextroamphetamine, 50, 51t

Diazepam, IM, 64

Diffusion-controlled release mechanisms,  
 37

Diuretics, kidney and, 92–93

Dose dumping, 129–130

Drug abuse, gender differences, 192

Drug allergies, genes for, 173–174

Drug distribution, elderly patients,  
 182–183

Drug formulation, 7–14

Drug-induced liver impairment, 79–80

Drug interactions, 99–107, 109–115  
 antipsychotics, 117–124  
 keeping up with, 102

by medication, 200–210t

mood stabilizers, 117–124

pharmacodynamic, 135–152

recreational, 131–134, 132t

toxic, 105t

Drug metabolism, 3–5, 75

children, 186–187

elderly patients, 181–186

ethnicity and, 193–195

generic drugs, 155–167

liver disease and, 78–84

Drug withdrawal, 26

Duloxetine, 38

## E

Effexor. *see* Venlafaxine XR

Elderly patients

dosing in, 185–186

drug metabolism in, 181–186

Elimination, 75

EMSAM. *see* Selegiline patch (EMSAM)

Enzyme family, interactions by, 211–212


Enzyme family chart, how to use, 198–199

Epocrates, 102

Equetro. *see* Carbamazepine

Eskalith. *see* Lithium

Esketamine, 58



Sample Page

# Prescribing Psychotropics: From Drug Interactions to Genetics

Available with 10 CME Credits at [www.thecarlatreport.com](http://www.thecarlatreport.com)

Excretion, 75, 85–95

aging kidneys, 183–185

children, 186–187

Exelon. *see* Rivastigmine patch

## F

Fetzima. *see* Levomilnacipram

Fluoxetine, 30, 31, 109

weekly, 42

Fluphenazine, 68

Fluvoxamine, 31, 109–111

medications raised by, 111t

Focalin XR capsules, 37

Food and drink, effects on medications,  
125–130

## G

Gabapentin, 31–32

Gender differences, medications, 189–192

Generic drugs, 155–167

authorized and branded, 157–158

bioequivalence, 156–157

MR medications, dose dumping and,  
129–130

pharmacy dispensing of, 158

in psychiatry, 158–160, 159t

Genetic testing. *see also* Pharmacogenetic  
testing

value of, 178–180

Geodon. *see* Ziprasidone

Ghost pills, 37

GI absorption, 15–20, 16f

Glomerular filtration rate (GFR), 88, 88t

Glucuronidation, 77

Grapefruit, medication levels and, 129,  
129t

## H

Haldol. *see* Haloperidol

Half-life, 3, 22

29t, 30–31

Hydrochlorothiazide, 92

Hydrolysis, 76–77

Hypertensive crisis, MAOIs and cheese,  
137–139

## I

Inactive ingredients, allergic reactions to,  
13–14

Induction, 100

Inhibition, 100

Inhibitors and inducers, 104t

Injectable medications, 61–73

Injection sites, 62

Intramuscular (IM) injections

for agitation, 61–66, 65t

short-acting, 61–62

short-acting antipsychotics, 63–64

Intranasal medications, 58–59

Intravenous medications, 72–73, 72t

Invega. *see* Paliperidone

Invega Sustenna. *see* Paliperidone

Invega Trinza. *see* Paliperidone

## K

Kidney, lithium and, 91–94

Kidney disease, chronic, stages of, 88t

Kidney impairment

after medication doses, 88–91

dosage adjustments needed, 90–91t

lithium and, 93–94

## L

Lamictal. *see* Lamotrigine

Lamotrigine, 46, 122

Lean-forward method for capsules, 9f

Levitra. *see* Vardenafil

Levomilnacipram, 38

Lexi-Interact, 102

Lisdexamfetamine, 51


Lithium, 29–30, 30f

drug interactions, 122–124

## Sample Page

# Prescribing Psychotropics: From Drug Interactions to Genetics

Available with 10 CME Credits at [www.thecarlatreport.com](http://www.thecarlatreport.com)



Liver disease. *see also* specific disease  
drug metabolism and, 78–84  
type common in psychiatric practice,  
79–82

Liver function tests, 82  
common, 82t  
interpretation of, 82–84

Long-acting injectable medications, 66–71,  
69t

Lorazepam  
IM, 64  
IV, 72

Loxapine, inhaled, 59–60

## M

### MAOIs

antidepressant augmentation of, 146  
cheese and, 137–139  
modernized diet for, 142t  
serotonin syndrome and, 143  
transdermal, 53–54  
washout period, 146–147

Medication chart, how to use, 197–198

Metabolic polypharmacy, 113, 114t

Metabolizer status, relevance of, 170–173

Methamphetamine, 52

Methylphenidate patch, 56

Methylphenidates, 48–50

formulations, 49t

Midazolam, IM, 64–65

Modafinil, 27

Modified-release (MR) formulations, 17,  
22, 33–52

dosing convenience, 34–35

ghost pills, 37

how they work, 33–34

pros and cons, 34, 34t

side effects and, 36

splitting and crushing, 35, 35–36t

substance use disorders and, 37

Multitargeted modulators

drug interactions, 117–124

Nonalcoholic fatty liver disease, 80  
NSAIDs, 92–93

lithium levels and, 122–124

Nuvigil. *see* Armodafinil

## O

Olanzapine, 12–13  
long-acting IM, 70  
plus benzos, 63–64  
short-acting IM, 63

Oleptro. *see* Adderall

Onset of action, 21–22

### Opioids

dose dumping and, 130

drug interactions, 133–134

pharmacodynamic drug interactions,  
135–137

use of benzos with, 136t

Oral contraceptives, drug interaction, 122t

Oral inhalation medication, 59–60

Orally disintegrating tablets (ODTs),  
10–11, 11t

Oxidation, 76–77

Oxytocin, 59

## P

P450 system, 75–76

Paliperidone, 37, 46, 69–70

Paroxetine, 26, 31, 42, 109

Patent extenders, 165–166, 166–167t

Paxil. *see* Paroxetine

P-glycoprotein, medications impacted by,  
178t

Pharmacodynamic genes, 169–170

Pharmacodynamics, drug interactions,  
135–152

Pharmacogenetic testing, 169–179

recommendations from the FDA, 172t  
SERT gene and, 194

Pharmacogenomic algorithms, 174–177


Pharmacokinetic genes, 169–170

dosing adjustments for, 172t

## Sample Page

# Prescribing Psychotropics: From Drug Interactions to Genetics

Available with 10 CME Credits at [www.thecarlatreport.com](http://www.thecarlatreport.com)



Phase II reactions, 77–78

Pills

vs capsules, 8

definition, 7

expiration myth, 14

pros and cons, 8t

POLG, 174

Potency, vs effectiveness, 32

Prescription abbreviations, 8t

Pristiq. *see* Desvenlafaxine tablets

Prodrugs, 100–101

Prolixin deconoate. *see* Fluphenazine

Protein binding, 106–107, 106t

elderly patients, 185–186

Provigil. *see* Modafinil

Prozac. *see* Fluoxetine

Psychiatric drugs

interactions by enzyme family, 211–212t

interactions by medication, 200–210t

Psychiatric medications, risk of torsades de pointes with, 151t

Psychostimulants, generic, 162

Psychotropics

gender differences, 191–192, 192t

orally disintegrating version, 11t

## Q

QTc burden, 149–152

Quetiapine, 46–47, 118–119

Quetiapine XR, dose dumping, 130

## R

Recreational drug interactions, 131–134, 132t

Reduction, 76–77

Renal excretion, 85–94

aging kidneys, 183–185

Renal function. *see also* Kidney

assessment of, 86–88, 87f

Reversal, 100

Risperdal. *see* Risperidone

done, 69t, 70–71

Sedatives, half-life of, 23–26, 25t

Selegiline patch (EMSAM), 53–54, 139–141

Seroquel. *see* Quetiapine

Serotonergic antidepressants, 26

Serotonin, gender differences, 190–191

Serotonin reuptake transporter gene. *see* SERT gene

Serotonin syndrome, 143–144

specific drug combinations, 144–145, 145t

SERT gene, 176

pharmacogenetic testing and, 194

Side effects

ethnicity and, 194–195

gender differences, 191–192, 192t

Smoke/smoking, pharmacokinetic

interactions, 131–132, 133t

Sodium divalproex. *see* Valproic acid (valproate)

Sonata. *see* Zaleplon

SSRIs

drug interactions, 109–110

QTc burden, 150

serotonin syndrome and, 143

Steady state, 29–30

Stevens-Johnson syndrome (SJS), 173

Stimulants, 47–52

half-life of, 23–26, 24t

Subcutaneous injections, 71–72

Substrate, 99

Swallowing

difficulty, 9

techniques for improvement, 10t

## T

Tegretol. *see* Carbamazepine

Tegretol XR. *see* Carbamazepine XR

Thorazine. *see* Chlorpromazine


Thyroid medication, generic, 163–165

Tmax, 21–22

## Sample Page

# Prescribing Psychotropics: From Drug Interactions to Genetics

Available with 10 CME Credits at [www.thecarlatreport.com](http://www.thecarlatreport.com)



Tyramine

in the diet, 141–142  
MAOI interaction, 137–139, 140f

V


Valium. *see* Diazepam  
Valproate, 31, 121, 121t  
Valproic acid (valproate), 43–45  
Vardenafil, QTc burden, 150  
Vegan/vegetarian medicines, 7–8  
Venlafaxine XR, 37, 38  
Versed. *see* Midazolam  
Victim drug  
    adjustment, 103t, 200t  
Volume of distribution (Vd), 18–19  
Vyleesi. *see* Bremelanotide  
Vyvanse. *see* Lisdexamfetamine

W

Water bottle method for tablets, 9f  
Wellbutrin. *see* Bupropion

Z

Zaleplon, 24  
Ziprasidone, IM, 64  
Zolpidem  
    dissolvable formation, 13  
    gender differences in dosing, 189–190  
    sprayable, 59  
Zolpimist. *see* Zolpidem  
Z-track method of injection, 62  
Zulresso. *see* Brexanolone  
Zyprexa. *see* Olanzapine



Sample Page

**Prescribing Psychotropics:  
From Drug Interactions to Genetics**

Available with 10 CME Credits at [www.thecarlatreport.com](http://www.thecarlatreport.com)

“Not only useful, but engaging and entertaining.”

—S. Nassir Ghaemi, MD, MPH

## Prescribing Psychotropics: From Drug Interactions to Genetics

(Previously *Drug Metabolism in Psychiatry*)

*Prescribing Psychotropics* bridges the gap between the complexities of drug pharmacokinetics and everyday clinical practice, providing clinicians more insight into how psychiatric drugs behave (or misbehave!) once their patients take them. The book also includes a series of unusually practical charts and tables that prescribers will find invaluable as they make medication decisions.

### What you'll find inside

- ✓ The basics of drug metabolism
- ✓ What you really need to know about drug interactions
- ✓ Food and drink effects on medications
- ✓ Recreational drug interactions
- ✓ Gender and drug metabolism
- ✓ Drug metabolism and ethnicity
- ✓ More than 70 quick-reference tables, charts, and figures



#### Chris Aiken, MD

Dr. Aiken is the editor-in-chief of *The Carlat Psychiatry Report* and hosts *The Carlat Psychiatry Podcast*. He is the director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials and conducts research on a shoestring budget out of his private practice.



#### Joshua D. Feder, MD

Dr. Feder is the editor-in-chief of *The Carlat Child Psychiatry Report* and contributes to *The Carlat Psychiatry Podcast*. Dr. Feder practices in Solana Beach, California and serves as medical director at Positive Development. He is an adjunct professor at Fielding Graduate University, participates in clinical research at UCSD and SDSU, develops technology for autism and related challenges, and is a senior consultant to the International Network for Peace Building with Young Children. He is a co-author of the *Child Medication Fact Book for Psychiatric Practice*.



#### Daniel J. Carlat, MD

Dr. Carlat is the publisher of *The Carlat Psychiatry Report*, *The Carlat Child Psychiatry Report*, *The Carlat Addiction Treatment Report*, and *The Carlat Hospital Psychiatry Report*. He is the chair of psychiatry at Tufts-affiliated MelroseWakefield Healthcare and is associate clinical professor of psychiatry at Tufts University School of Medicine. He is the author of *The Psychiatric Interview* and previous editions of this book. He is also the co-author of the *Medication Fact Book for Psychiatric Practice*.

**C**ARLAT PUBLISHING

[www.thecarlatreport.com](http://www.thecarlatreport.com)

PO Box 626 • Newburyport, MA 01950

## Sample Pages

Available with 10 CME Credits at [www.thecarlatreport.com](http://www.thecarlatreport.com)